Testing effectiveness (Phase 2)Study completedNCT04739423
What this trial is testing
Clenbuterol (CST-103) Co-administered With Nadolol (CST-107) in Subjects With Neurodegenerative Disorders
Who this might be right for
Mild Cognitive Impairment, Lewy Body Dementia, Parkinson's Disease Rapid Eye Movement Sleep Behavior Disorder, Parkinson's Disease Dementia
CuraSen Therapeutics, Inc. 41